Structures of Human Acetylcholinesterase Bound to Dihydrotanshinone I and Territrem B Show Peripheral Site Flexibility
Citations Over TimeTop 10% of 2013 papers
Abstract
Acetylcholinesterase is a critical enzyme that regulates neurotransmission by degrading the neurotransmitter acetylcholine in synapses of the nervous system. It is an important target for both therapeutic drugs that treat Alzheimer's disease and chemical warfare agents that cripple the nervous system and cause death through paralysis. The enzyme has both catalytic and peripheral sites to which inhibitors may bind. Structures of recombinant human acetylcholinesterase in complex with the natural product inhibitors dihydrotanshinone I and territrem B reveal dihydrotanshinone I binding that is specific to only the peripheral site and territrem B binding that spans both sites and distorts the protein backbone in the peripheral site. These inhibitors may function as important molecular templates for therapeutics used for treatment of disease and protection against nerve agents.
Related Papers
- → Acetylcholine release from frontal cortex in the waking rat measured by microdialysis without acetylcholinesterase inhibitors: effects of diisopropylfluorophosphate(1996)21 cited
- → Acetylcholinesterase and Acetylcholine Receptors: Brain Regional Heterogeneity(2011)8 cited
- → Influence of acetylcholine on rebinding of soluble acetylcholinesterase to a synaptosomal fraction from rat brain(1980)3 cited
- Virtual high-throughput screening of insect acetylcholinesterase inhibitors(2018)